Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioNTech SE | Combined influenza and COVID-19 Vaccine | Vaccine candidate against influenza and COVID-19 | Phase 3 | Data Released | Intramuscular | COVID-19 |
| BioNTech SE | Autogene cevumeran (BNT122/RO7198457) - (IMCODE004) | High-risk muscle-invasive urothelial carcinoma (MIUC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| BioNTech SE | BNT323/DB-1303 | Advanced endometrial cancer | Phase 3 | Ongoing | Intravenous | Oncology |
| BioNTech SE | Gotistobart (BNT316/ONC-392) with lutetium Lu 177 vipivotide tetraxetan (Lu 177) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | Ongoing | Intravenous | Oncology |
| BioNTech SE | BNT327/PM8002 with chemotherapy | Triple negative breast cancer | Phase 3 | IND Clearance | Intravenous | Oncology |
| BioNTech SE | Autogene cevumeran (BNT122) | 1L Metastatic Melanoma | Phase 2 | Ongoing | Intravenous | Oncology |
| BioRestorative Therapies Inc | BRTX-100 | Chronic lumbar disc disease | Phase 2 | Data Released | Intraosseous | Orthopedic |
| BioVie Inc. | BIV201 | Ascites | Phase 2b | Trial Planned | Intravenous | Gastroenterology |
